Loading stock data…
NUVB
$4.92+0.13 (+2.60%)
After Hours$4.93+0.00 (+0.10%)· Last close Jun 9
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing product candidates for cancer treatment.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Nuvation Bio Inc. in the Healthcare sector is trading at $4.92. Wall Street consensus targets $12.33 (9 analysts), implying a +150.4% move over the next 12 months. The stock is currently 49% below its 52-week high of $9.75, remaining 6.2% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +150.4% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$4.92
Potential Downside
0%
Whystock Fair Value$4.92
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing product candidates for cancer treatment. The company's lead product candidate is IBTROZI (taletrectinib), a ROS1 inhibitor for the treatment of patients with ROS1+ n...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
-
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-45.69%
Volume
Today's trading volume
9.37M
Recent News
Nuvation Bio Sharpens IBTROZI Focus With Thermo Fisher And FDA Steps
Nuvation Bio (NYSE:NUVB) has completed a technology transfer partnership with Thermo Fisher Scientific for manufacturing IBTROZI. The company announced that the FDA has accepted a supplemental New Drug Application for IBTROZI, supported by new long term data. Updated IBTROZI clinical results in advanced ROS1 positive NSCLC were recently presented at the AACR Annual Meeting. Nuvation Bio comes into these IBTROZI updates with a share price of $4.32 and a mixed return profile. The stock is...
Thermo Fisher Deepens Oncology Role With Ibtrozi Manufacturing Milestone
Thermo Fisher Scientific (NYSE:TMO) has completed technology transfer and product introduction for Ibtrozi, a treatment for ROS1-positive non-small cell lung cancer. This marks a key milestone in its collaboration with Nuvation Bio and reflects a deeper role in biopharma manufacturing and oncology drug commercialization. For investors watching NYSE:TMO, this update highlights the company’s position as a partner for complex drug production in cancer care, not just a supplier of equipment and...
Bicara Stock Is Up 50%, and One Biotech Investor Has Made It a 29% Portfolio Bet
This clinical-stage biotech develops bifunctional antibody therapies targeting solid tumors for oncology providers and institutions.
Alumis Stock Is Up Over 300%. One Major Healthcare Investor Is Cutting Back
Alumis Inc. develops clinical-stage therapies targeting autoimmune and neuroinflammatory diseases using allosteric TYK2 inhibitors.
Kestra Medical Grew Revenue 63%. One Fund Still Trimmed 351,000 Shares
Kestra Medical Technologies develops advanced wearable cardiac devices and digital health solutions for cardiovascular care providers.